3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Influenza, Human
10
Neoplasms
6
Neoplasms, Plasma Cell
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Acute
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia
2
Colorectal Neoplasms
2
Central Nervous System Neoplasms
2
Waldenstrom Macroglobulinemia
1
Virus Diseases
1
Vaccine-Preventable Diseases
1
Vaccination Hesitancy
1
Sezary Syndrome
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Patient Acceptance of Health Care
1
Oligodendroglioma
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Interventions
Tea
2
Bupivacaine
2
Tadalafil
1
Supine Position
1
Morphine
1
Ketamine
1
Injections, Subcutaneous
1
Influenza Vaccines
1
Head-Down Tilt
1
Dexmedetomidine
1
Anesthetics, Local
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Abdominal Cancer
×
Influenza Vaccines
×
Clear all
NCT02998736
2022-12-28
PERIOP-04
Ottawa Hospital Research Institute
Phase 1
Completed
28 enrolled